Bethesda Classification

"Bethesda Classification" refers to two distinct, unrelated grading systems in medicine that share the name (from the 1988/2001 NCI consensus conferences held in Bethesda, Maryland). Which one applies depends on context:

1. Bethesda System for Reporting Thyroid Cytopathology (most common use in surgery/endocrinology)

Used to standardize reporting of thyroid fine-needle aspiration (FNA) biopsy results. It has six diagnostic categories, each with an associated risk of malignancy and suggested management - endorsed by the American Thyroid Association (ATA) - Mulholland and Greenfield's Surgery, 7e.

Category	Diagnosis	Risk of Malignancy	Usual Management
I	Nondiagnostic/unsatisfactory	~1-4% predicted (actual series ~9-32%)	Repeat FNA with US guidance
II	Benign	<3%	Clinical/US follow-up
III	Atypia of undetermined significance / follicular lesion of undetermined significance (AUS/FLUS)	~6-18%	Repeat FNA, molecular testing, or lobectomy
IV	Follicular neoplasm / suspicious for follicular neoplasm	~10-40%	Diagnostic lobectomy or molecular testing
V	Suspicious for malignancy	~45-60%	Near-total thyroidectomy or lobectomy
VI	Malignant	~94-96%	Thyroidectomy (extent per tumor characteristics)

Key points:

Categories I and II are highly accurate (error rate <3%) - Sabiston Textbook of Surgery.
Categories III and IV ("indeterminate") are the most clinically challenging; management may include repeat FNA, molecular genetic testing (e.g., RAS mutations, gene expression classifiers), or diagnostic surgery - Creasy & Resnik's Maternal-Fetal Medicine.
Category V/VI lesions should generally be managed surgically.

A recent systematic review/meta-analysis (2025) evaluated RAS mutation testing specifically to refine risk stratification within Bethesda category IV nodules, reflecting ongoing efforts to improve the indeterminate categories (PMID: 41450928). This doesn't overturn the classification itself, just adds molecular refinement for indeterminate categories.

2. Bethesda System for Reporting Cervical Cytology (Pap smear)

Used to standardize Pap smear/cervical cytology reporting. Per the 2001 revision (Swanson's Family Medicine Review), key terms include:

ASC - atypical squamous cells
ASC-US - atypical squamous cells of undetermined significance
ASC-H - atypical squamous cells, cannot exclude HSIL
LSIL - low-grade squamous intraepithelial lesion
HSIL - high-grade squamous intraepithelial lesion
AGC - atypical glandular cells
Correlates with histologic CIN (cervical intraepithelial neoplasia) grading

Management of ASC-US typically involves either repeat cytology, HPV DNA triage (referral to colposcopy if high-risk HPV positive), or immediate colposcopy, with HPV-based triage showing 90-96% sensitivity for detecting high-grade lesions versus 75-85% for repeat Pap testing alone.

If you meant a specific one (thyroid nodule workup vs. Pap smear/cervical screening vs. the Bethesda coagulation factor-inhibitor assay, which is a different, unrelated "Bethesda unit" concept in hematology), let me know and I can go deeper into that specific system.

This is a shared conversation. Sign in to Orris to start your own chat.